Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis.

Jane J Kim Kate T Simms James Killen Megan A Smith Emily A BurgerStephen SyCatherine ReganKaren Canfell

Published in: PLoS medicine (2021)

Our results from 2 independent models suggest that HPV vaccination for adult women and men aged 30 to 45 years is unlikely to represent good value for money in the US.

Keyphrases

polycystic ovary syndrome
cervical cancer screening
high grade
middle aged
type diabetes
insulin resistance
data analysis